Detailed Information

Cited 16 time in webofscience Cited 18 time in scopus
Metadata Downloads

Comparison of Clevudine and Entecavir for Treatment-naive Patients With Chronic Hepatitis B Virus Infection Two-Year Follow-up Data

Authors
Yoon, Eileen L.Yim, Hyung JoonLee, Hyun JungLee, Young SunKim, Jeong HanJung, Eun SukKim, Ji HoonSeo, Yeon SeokYeon, Jong EunLee, Hong SikUm, Soon HoByun, Kwan Soo
Issue Date
Nov-2011
Publisher
Lippincott Williams & Wilkins Ltd.
Keywords
chronic hepatitis B; treatment; clevudine; entecavir; resistance
Citation
Journal of Clinical Gastroenterology, v.45, no.10, pp.893 - 899
Indexed
SCIE
SCOPUS
Journal Title
Journal of Clinical Gastroenterology
Volume
45
Number
10
Start Page
893
End Page
899
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/13039
DOI
10.1097/MCG.0b013e31821f8bdf
ISSN
0192-0790
Abstract
Background/Aim Clevudine and entecavir are highly potent antiviral agents being used in treatment of chronic hepatitis B. However, no data comparing clinical efficacy and safety of these 2 drugs over a long-term period is available. The aims of this study are to compare virologic, biochemical, and serologic response rates of clevudine and entecavir, as well as treatment failure rates up to 2 years. Methods Data of patients who started clevudine (n=86) or entecavir (n=159) as a primary treatment for chronic hepatitis B at Korea University Ansan or Guro Hospital between January 2007 and June 2008 were analyzed. Results Treatment responses were compared at 3-month intervals up to 24 months. Per protocol analysis showed no difference in virologic responses between the 2 groups at all time points, except at 18 months. When analyzed on intention-to-treat basis for virologic response at 24 months, the response rates were 45.3% in the clevudine group and 72.3% in the entecavir group, which are significantly different (P<0.001). Rates of biochemical response and HBeAg seroconversion were not significantly different between the groups at all time points. Up to 24 months, antiviral resistance developed in 18 patients (24.4%) in the clevudine group. Clevudine was discontinued owing to muscle-related problems in 10 patients (11.6%). Conclusions Although both drugs showed potent antiviral activity, entecavir showed better virologic response at 24 months, primarily owing to treatment failures in the clevudine group that were associated with development of drug resistance and muscle-related problems.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE